Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparative Trials For Contraceptives Recommended By FDA Advisory Panel

Executive Summary

Actively controlled comparative trials should be the new paradigm for registration studies of hormonal contraceptives, FDA's Advisory Committee on Reproductive Health Drugs told the agency Jan. 23

You may also be interested in...



Lybrel Label Details Breakthrough Bleeding; Studies Had High Drop-Out Rate

Wyeth could encounter resistance to uptake of its continuous oral contraceptive Lybrel due to high initial rates of intermenstrual bleeding and spotting

Lybrel Label Details Breakthrough Bleeding; Studies Had High Drop-Out Rate

Wyeth could encounter resistance to uptake of its continuous oral contraceptive Lybrel due to high initial rates of intermenstrual bleeding and spotting

Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA

FDA's draft guidance on patient-reported outcomes (PROs) should offer both greater flexibility and detail, industry commenters told the agency

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel